Embed Size (px)
Citation preview
Strategic priority for AMR
Transforming our response to drug resistant infections
Ghada Zoubiane PhD
Science Lead – Drug-Resistant Infections priority programme
Joint Programming Initiative on AMR – MB meeting 26 January 2018, Brussels
Where we work
Malawi-Liverpool-
Wellcome Clinical
Research
Programme
Africa Health Research
Institute (AHRI)
KEMRI-Wellcome
Research
Programme
Vietnam Research
Programme and
Oxford University
Clinical Research
Unit
Wellcome-Mahidol
University-Oxford
Tropical Medicine
Research Programme
Brazil
Cameroon
China
Switzerland
Peru
Benin
Kenya
Tanzania
South Africa
Ghana
Senegal
United Kingdom
France
United States
Denmark
India
Colombia Ivory Coast
Australia
Spain
Ireland Belgium Hungary
Wellcome has invested £287m in AMR
activities since 2004, including:
• basic science (£108),
• translation (£122m)
• surveillance/epidemiology (£34m)
Funding research globally to tackle AMR
Wellcome’s priority programme
Wellcome’s framework for supporting science
Advancing ideas
We support great ideas
and inspired thinking
Seizing opportunities
We bring ideas together
to make a difference
Driving reform
We change ways of
working so more ideas can
flourish
Wellcome’s new strategic framework
Seizing opportunities
We bring ideas together to make a big difference
We identify times when our concerted intervention can accelerate progress towards
better health.
We identify a critical need and set ambitious goals.
We connect experts from different disciplines, build partnerships, and lead advocacy, policy
development, communications and public engagement.
We do this by providing focused, intensive support that creates a step change over five to
ten years.
• Will be
Outcome / objective led
Targeting research activities to deliver outcomes
Commissioning work and inviting requests for proposals
Influencing & advocating
Building and catalysing partnerships
• Response-mode funding (Advancing Ideas) will still support AMR research
as it always has
• Not a broad funding scheme for AMR
• Not pulling all AMR activities under one umbrella7
Wellcome’s priority programme focused on AMR
Seeking to transform the response to the threat of AMR by improving treatments,
enabling policy and engaging communities
Near-term goals Long-term goals
• Understanding emergence and transmission of AMR
• Increased pipeline of new therapeutics and diagnostics, and optimisation of existing Tx
• Accelerating development of new treatments for patients
• Coordinating activities toward common goals
• Paradigm shift in preventing and treating infections
• Coordinated international response to make healthcare systems resilient to threat of resistance
• Public mandate for change
Developing Wellcome Trust’s strategic priority
Evidence for
decision making
Effective
global
governance
Faster clinical
trialsclinical
New treatments
Expertise
Resources
Wellcome is creating a
global portfolio of open
research and data to help
guide national and global
strategies for tackling drug-
resistant infections.
Working with partners,
Wellcome is funding the
development of potential new
antibiotics, diagnostics and
preventative approaches.
Wellcome is working with
policy makers to support the
development of a global
framework to coordinate,
monitor and evaluate progress.
With partners around the
world, Wellcome is building
global clinical trial networks
to innovate and standardise
protocols and make trials
more efficient.
9
Drug-resistant
infections
£175m over
5 years
Four pillars
How we work and managing delivery
Supporting – investing in projects and activities
Facilitating – working with others to achieve shared goals
Influencing – persuade others to act
10
Drug-Resistant Infection is a
global health threat that
undermines the progress
made in the fight against
infectious disease in the last
century.
11
Evidence for decision making
• Surveillance and Epidemiology of
Drug Resistant Infections
Consortium (SEDRIC)
• Global burden of antimicrobial
resistance mapping project: Institute
for Health Metrics and Evaluation and
Big Data Institute at Oxford University
• Making industry antibiotic
surveillance data open access –
Open Data Institute
• Joint WHO project for behaviour
change
Launching SEDRIC
12
Board convened January 12th. Public launch January 30th as a side event
at Prince Mahidol Awards Conference.
13
www.wellcome.ac.uk/sedric
14
New treatments
• CARB-X
• Drug discovery pipeline
• £125m over 5 years with 34 projects so far
in 7 countries (including India)
• Global Antibiotic Research and Development
Partnership (GARDP) to work in partnership
with the public and private sectors to develop
and deliver new treatments for bacterial
infections for which inadequate treatment exists
• Diagnostics
• Innovative Medicines Initiative to support
the development of diagnostics
• Joint WHO project to develop Target
Product Profiles for diagnostics
CARB-X Funding Rounds for 2018Supporting innovation to fight drug-resistant bacteria
Kevin Outterson
3/5/2018
15
What CARB-X funds
• Early development projects that address the serious bacterial threats
– antibiotics and therapeutics of all types
– rapid diagnostics
– preventives such as vaccines, microbiome
• Projects that target bacteria on the Antibiotic Resistance Threats List issued by the Centers for Disease Control and Prevention (CDC) in 2013 or on the Priority Bacterial Pathogens Listpublished by the World Health Organization (WHO) in 2017
CARB-X funds projects in early development
CARB-X 2018 Funding Round 1
• Scope of Round 1
– New classes of direct-acting small molecule antibiotics and large molecule drugs that target priority Gram-negative bacteria
• Expressions of Interest (EOI) accepted on-line only www.carb-x.org/application
• EOI must be submitted March 22 through March 29, 2018, 5 pm EST
Applying for Round 1? Mark your calendar
March 22 – 29, 2018
CARB-X 2018 Funding Round 2
• Scope of Round 2
– Broad scope of therapeutics, vaccines, diagnostics and devices
• Expressions of Interest (EOI) accepted on-line only www.carb-x.org/application
• EOI must be submitted June 1 through June 8, 2018, 5 pm EST
Applying for Round 2?Mark your calendar
June 1 - 8, 2018
Applying for CARB-X funding, in summary
• CARB-X welcomes applications from around the world
• Expressions of Interest applications must be submitted on-line at www.carb-x.org/application
• To qualify for funding and support, projects must be in scope and organizations must meet certain criteria
• The Powered by CARB-X portfolio is the world’s largest and most scientifically diverse portfolio of early development antibacterial products to respond to the threat of the most serious drug-resistant bacteria
More information: www.carb-x.org
CARB-X 2018 Funding Rounds will open for Expressions of Interest Round 1: March 22-29, 2018Round 2: June 1-8, 2018
23
Faster clinical trials
Accelerated clinical
development of new drugs and
improved use of existing drugs
• Global clinical trial networks
(GCTN) to support design,
operation and interpretation
• Antibiotic Master Protocol
Alliance (AMPA) to
accelerate registration of new
treatments
24
Effective global governance
• Helping governments (and others) develop
and implement effective policies to limit the
development and spread of drug-resistant
infections
• Advocating for ambitious, sustained action
– e.g. access and stewardship, new incentive
models for antibiotic development
• Global AMR Collaboration Hub (led by
Germany) will help coordinate global R&D and
serve to inform political decisions for investing
• Work with UN agencies including WHO to
develop and support delivery of the
Interagency Coordination Group
25
Team
26
Tim Jinks
Head of programme
Policy & Advocacy
Lead
Jeremy Knox
Strategic
Advisory
Group
Operations Manager
Communications manager
Admin supportTechnical
Advisory
Groups
Science & Innovation
Lead
Ghada Zoubiane
Alyson Fox
(Sponsor)Expert in Residence
John Rex
Ed Whiting
Francesca Chiara
Janet Midega
Joanna Wiecek
Sian Williams
Rebecca Sugden
Expert in Residence
Sharon Peacock
Support from Legal, GM, I&A, Finance & Communincations
James HynardIn Global Policy Team
